Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.47 |
| ▸ | F2 | P00734 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPN | P05981 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778043 | 0.88 | F10 (0.61) | F10PRSS1F2HPNHGFAC | |
| SCHEMBL6784570 | 0.80 | F10 (0.49) | F10PRSS1F2 | |
| SCHEMBL6780731 | 0.78 | F10 (0.46) | F10PRSS1F2ALDH1A1MAPT | |
| SCHEMBL6780268 | 0.78 | F10 (0.46) | F10PRSS1F2KDM4ETSHR | |
| SCHEMBL6775750 | 0.78 | MAPT (0.51) | F10PRSS1F2KDM4ETSHR | |
| SCHEMBL6897423 | 0.78 | F10 (0.48) | F10PRSS1F2 | |
| SCHEMBL27579772 | 0.78 | F10 (0.50) | F10PRSS1F2 | |
| SCHEMBL5918522 | 0.77 | F10 (0.70) | F10PRSS1F2HPNPRSS2 | |
| SCHEMBL6778302 | 0.76 | POLB (0.45) | F10PRSS1F2KDM4EST14 | |
| SCHEMBL6784222 | 0.74 | F10 (0.42) | F10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794507-B2 | Compounds that inhibit factor Xa activity | MORPHOCHEM AG (DE) | 2004-09-21 | — | — | US | disclosed |
| CN-1460101-A | Novel compounds that inhibit factor Xa activity | MORPHOCHEM AG (DE) | 2003-12-03 | — | — | CN | disclosed |
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | CAPPI MICHAEL W (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | SERPINC1, F11, TFPI | F10 6/4885PRSS1 51/4885F2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.